Evaxion Biotech AS (Evaxion Biotech AS) ROCE % : -206.86% (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Evaxion Biotech AS ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Evaxion Biotech AS's annualized ROCE % for the quarter that ended in Dec. 2023 was -206.86%.

Evaxion Biotech AS ROCE % Historical Data

The historical data trend for Evaxion Biotech AS's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Evaxion Biotech AS ROCE % Chart

Evaxion Biotech AS Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-255.42

-201.78

-114.52

-85.55

-182.96

Evaxion Biotech AS Quarterly Data
	Dec18	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %	Get a 7-Day Free Trial														-125.40	-126.12	-135.70	-184.70	-206.86

Evaxion Biotech AS ROCE % Calculation

Evaxion Biotech AS's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-22.018	/	( ( (22.025 - 3.762)	+	(12.889 - 7.084) )	/ 2 )
	=	-22.018	/	( (18.263	+	5.805)	/ 2 )
	=	-22.018	/	12.034
	=	-182.96 %

Evaxion Biotech AS's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	-18.356	/	( ( (11.942 - 0)	+	(12.889 - 7.084) )	/ 2 )
	=	-18.356	/	( ( 11.942	+	5.805 )	/ 2 )
	=	-18.356	/	8.8735
	=	-206.86 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

Evaxion Biotech AS (NAS:EVAX) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Evaxion Biotech AS ROCE % Related Terms

Thank you for viewing the detailed overview of Evaxion Biotech AS's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Evaxion Biotech AS (Evaxion Biotech AS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Evaxion Biotech AS (NAS:EVAX) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Dr. Neergaards Vej 5f, Hoersholm, DNK, DK-2970

Website

https://www.evaxion-biotech.com

Evaxion Biotech AS is a clinical-stage biotech company that aspires to the exploration of artificial intelligence, or AI, to develop immunotherapies with improved efficacy when compared to currently marketed products for patients with unmet medical needs. Its pipeline programs are derived from its proprietary AI platforms, PIONEER, EDEN, RAVEN, and ObsERV. The company is utilizing these AI platforms to build a drug development pipeline. Its product candidates are; EVX-01 and EVX-02, for the treatment of various cancers, and the third candidate is cancer immunotherapy, EVX-03, for the treatment of various cancers including non-small-cell-lung-cancer, or NSCLC, is in pre-clinical development.